A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Yan L, Rosen N, Arteaga C. Targeted cancer therapies. Chin J Cancer 2011; 30:1 - 4; http://dx.doi.org/10.5732/cjc.010.10553; PMID: 21192839
   PubMedGoogle Scholar
• Abdullah C, Wang X, Becker D. Molecular therapy for melanoma: useful and not useful targets. Cancer Biol Ther 2010; 10:113 - 8; http://dx.doi.org/10.4161/cbt.10.2.12595; PMID: 20574152
   PubMed Web of Science ®Google Scholar
• Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19:21 - 34; PMID: 10840932
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158 - 66; PMID: 10623706
   PubMed Web of Science ®Google Scholar
• Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6:Suppl 1 S11 - 4; PMID: 10685652
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 - 26; http://dx.doi.org/10.1056/NEJMoa1104621; PMID: 21639810
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507 - 16; http://dx.doi.org/10.1056/NEJMoa1103782; PMID: 21639808
   PubMed Web of Science ®Google Scholar
• Umansky V, Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother 2012; 61:275 - 82; http://dx.doi.org/10.1007/s00262-011-1164-6; PMID: 22120757
   PubMed Web of Science ®Google Scholar
• Javeed A, Ashraf M, Riaz A, Ghafoor A, Afzal S, Mukhtar MM. Paclitaxel and immune system. Eur J Pharm Sci 2009; 38:283 - 90; http://dx.doi.org/10.1016/j.ejps.2009.08.009; PMID: 19733657
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu N, Xiong SD, Zheng YJ, Chu YW. CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. Scand J Immunol 2011; 73:301 - 8; http://dx.doi.org/10.1111/j.1365-3083.2011.02514.x; PMID: 21223350
   PubMed Web of Science ®Google Scholar
• Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010; 8:71; http://dx.doi.org/10.1186/1479-5876-8-71; PMID: 20653948
   PubMed Web of Science ®Google Scholar
• Yuan L, Wu L, Chen J, Wu Q, Hu S. Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Vaccine 2010; 28:4402 - 10; http://dx.doi.org/10.1016/j.vaccine.2010.04.046; PMID: 20434553
   PubMed Web of Science ®Google Scholar
• Marin-Esteban V, Charron D, Gelin C, Mooney N. Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation. J Immunother 2010; 33:364 - 70; http://dx.doi.org/10.1097/CJI.0b013e3181cd1094; PMID: 20386470
   PubMed Web of Science ®Google Scholar
• Pfannenstiel LW, Lam SS, Emens LA, Jaffee EM, Armstrong TD. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 2010; 263:79 - 87; http://dx.doi.org/10.1016/j.cellimm.2010.03.001; PMID: 20346445
   PubMed Web of Science ®Google Scholar
• John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, et al. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol 2010; 11:14; http://dx.doi.org/10.1186/1471-2172-11-14; PMID: 20302610
   PubMed Web of Science ®Google Scholar
• Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009; 58:615 - 28; http://dx.doi.org/10.1007/s00262-008-0586-2; PMID: 18802696
   PubMed Web of Science ®Google Scholar
• Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009; 32:54 - 65; http://dx.doi.org/10.1097/CJI.0b013e31818b3dad; PMID: 19307994
   PubMed Web of Science ®Google Scholar
• Rettig L, Seidenberg S, Parvanova I, Samaras P, Curioni A, Knuth A, et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer 2011; 129:832 - 8; http://dx.doi.org/10.1002/ijc.25756; PMID: 21710545
   PubMed Web of Science ®Google Scholar
• Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9:900 - 9; http://dx.doi.org/10.1016/j.intimp.2009.03.015; PMID: 19336265
   PubMed Web of Science ®Google Scholar
• Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2009; 39:797 - 806; http://dx.doi.org/10.1093/jjco/hyp112; PMID: 19797418
   PubMed Web of Science ®Google Scholar
• Suzuki E, Sun J, Kapoor V, Jassar AS, Albelda SM. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther 2007; 6:880 - 5; http://dx.doi.org/10.4161/cbt.6.6.4090; PMID: 17582217
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713 - 21; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883; PMID: 16166452
   PubMed Web of Science ®Google Scholar
• Correale P, Tindara Miano S, Remondo C, Migali C, Saveria Rotundo M, Macrì P, et al. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. Cancer Biol Ther 2009; 8:497 - 502; http://dx.doi.org/10.4161/cbt.8.6.7593; PMID: 19242101
   PubMed Web of Science ®Google Scholar
• Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005; 23:8950 - 8; http://dx.doi.org/10.1200/JCO.2005.12.147; PMID: 16061910
   PubMed Web of Science ®Google Scholar
• Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res 2008; 14:4192 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-5278; PMID: 18593999
   PubMed Web of Science ®Google Scholar
• Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37:300 - 11; http://dx.doi.org/10.1016/j.ctrv.2010.11.001; PMID: 21126826
   PubMed Web of Science ®Google Scholar
• Guan H, Singh NP, Singh UP, Nagarkatti PS, Nagarkatti M. Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma. PLoS One 2012; 7:e35650; http://dx.doi.org/10.1371/journal.pone.0035650; PMID: 22532866
   PubMedGoogle Scholar
• Hornyak SC, Orentas DM, Karavodin LM, Gehlsen KR. Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice. Vascul Pharmacol 2005; 42:187 - 93; http://dx.doi.org/10.1016/j.vph.2005.02.011; PMID: 15820445
   PubMed Web of Science ®Google Scholar
• Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997; 37:117 - 32; http://dx.doi.org/10.1016/S0162-3109(97)00041-6; PMID: 9403331
   PubMed Web of Science ®Google Scholar
• McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009; 115:Suppl 2298 - 305; http://dx.doi.org/10.1002/cncr.24236; PMID: 19402060
   PubMed Web of Science ®Google Scholar
• Dutcher JP. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard. [Williston Park] Oncology (Williston Park) 2011; 25:427 - 8; PMID: 21710841
   PubMed Web of Science ®Google Scholar
• Kanai M, Matsumoto S, Nishimura T, Matsumura Y, Hatano E, Mori A, et al. Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy. Ann Oncol 2010; 21:189 - 90; http://dx.doi.org/10.1093/annonc/mdp513; PMID: 19889615
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105 - 16; PMID: 10561265
   PubMed Web of Science ®Google Scholar
• Bellón T, Blanca M. The innate immune system in delayed cutaneous allergic reactions to medications. Curr Opin Allergy Clin Immunol 2011; 11:292 - 8; PMID: 21659858
   PubMed Web of Science ®Google Scholar
• Ardern-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011; 71:672 - 83; http://dx.doi.org/10.1111/j.1365-2125.2010.03703.x; PMID: 21480947
   PubMed Web of Science ®Google Scholar
• Beer K, Oakley H. Clinical and histopathologic correlation of an eruption secondary to Taxotere. J Drugs Dermatol 2010; 9:1534 - 5; PMID: 21120264
   PubMed Web of Science ®Google Scholar